SGE-102: a novel therapy for refractory status epilepticus

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Refractory status epilepticus (RSE) carries a high mortality rate (up to 35%).
• Current RSE treatments involve anesthetics, but lack randomized trial data for agent selection.
• Medication resistance in SE may stem from synaptic GABA receptor internalization.

Purpose of the Study:

• To evaluate SGE-102, a neurosteroid, as an adjunctive therapy for RSE.
• To assess the efficacy of SGE-102 in preventing seizure recurrence after anesthetic discontinuation.
• To explore the role of neurosteroids acting on non-internalized GABAA receptors for RSE treatment.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving RSE patients.
• Subjects received midazolam plus either SGE-102 or placebo.
• Midazolam was tapered between 24-48 hours; SGE-102/placebo continued through 120 hours.

Main Results:

• The primary endpoint is seizure freedom through 120 hours post-initiation.
• Secondary endpoints include seizure freedom at 168 hours.
• The study is powered to detect a clinically meaningful reduction in seizure recurrence.

Conclusions:

• SGE-102, a progesterone metabolite, has demonstrated anticonvulsant properties in preclinical models.
• This trial will provide crucial data on the safety and efficacy of SGE-102 in managing refractory status epilepticus.
• Neurosteroids represent a potential novel therapeutic strategy for RSE.